313 related articles for article (PubMed ID: 26240235)
21. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
Nogová L; Rudiger T; Engert A
Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
[TBL] [Abstract][Full Text] [Related]
22. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications.
Koontz BF; Kirkpatrick JP; Clough RW; Prosnitz RG; Gockerman JP; Moore JO; Prosnitz LR
J Clin Oncol; 2006 Feb; 24(4):605-11. PubMed ID: 16446333
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.
Eichenauer DA; Fuchs M; Pluetschow A; Klimm B; Halbsguth T; Böll B; von Tresckow B; Nogová L; Borchmann P; Engert A
Blood; 2011 Oct; 118(16):4363-5. PubMed ID: 21828141
[TBL] [Abstract][Full Text] [Related]
24. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease.
Yildiz F; Zengin N; Engin H; Güllü I; Barista I; Caglar M; Ozyar E; Cengiz M; Gürkaynak M; Zorlu F; Caner B; Atahan IL; Tekuzman G
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):839-46. PubMed ID: 15465201
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.
Wirth A; Yuen K; Barton M; Roos D; Gogna K; Pratt G; Macleod C; Bydder S; Morgan G; Christie D
Cancer; 2005 Sep; 104(6):1221-9. PubMed ID: 16094666
[TBL] [Abstract][Full Text] [Related]
26. Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
Mocikova H; Pytlik R; Stepankova P; Michalka J; Markova J; Koren J; Buresova L; Raida L; Kral Z
Acta Haematol; 2015; 134(3):187-92. PubMed ID: 26021284
[TBL] [Abstract][Full Text] [Related]
27. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
Eichenauer DA; Engert A
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):324-328. PubMed ID: 29222274
[TBL] [Abstract][Full Text] [Related]
28. Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi.
Gobbi PG; Broglia C; Merli F; Dell'Olio M; Stelitano C; Iannitto E; Federico M; Bertè R; Luisi D; Molica S; Cavalli C; Dezza L; Ascari E
Cancer; 2003 Dec; 98(11):2393-401. PubMed ID: 14635074
[TBL] [Abstract][Full Text] [Related]
29. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
Illés A; Simon Z; Tóth E; Rosta A; Miltényi Z; Molnár Z
Pathol Oncol Res; 2008 Dec; 14(4):411-21. PubMed ID: 18431694
[TBL] [Abstract][Full Text] [Related]
30. Comparison of favorable early-stage hodgkin's lymphoma treatments: a single-institution review.
Samant R; Alomary I; Alsaeed E; Al-Jasir B; Bence-Bruckler I; Cross P; Genest P; Huebsch L
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1166-70. PubMed ID: 19695788
[TBL] [Abstract][Full Text] [Related]
31. Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Eroglu C; Kaynar L; Orhan O; Keklik M; Sahin C; Yildiz OG; Mentes S; Kurnaz F; Aslan D; Sivgin S; Soyuer S; Eser B; Cetin M; Unal A
Am J Clin Oncol; 2015 Feb; 38(1):68-73. PubMed ID: 23563207
[TBL] [Abstract][Full Text] [Related]
32. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).
Nogová L; Reineke T; Eich HT; Josting A; Müller-Hermelink HK; Wingbermühle K; Brillant C; Gossmann A; Oertel J; Bollen MV; Müller RP; Diehl V; Engert A
Ann Oncol; 2005 Oct; 16(10):1683-7. PubMed ID: 16093276
[TBL] [Abstract][Full Text] [Related]
33. How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA; Engert A
Blood; 2020 Dec; 136(26):2987-2993. PubMed ID: 32877522
[TBL] [Abstract][Full Text] [Related]
34. SOHO State of the Art Updates and Next Questions |Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Binkley MS; Advani RH
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):471-476. PubMed ID: 37076366
[TBL] [Abstract][Full Text] [Related]
35. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
[TBL] [Abstract][Full Text] [Related]
36. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group.
Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO
Leuk Lymphoma; 2004 Aug; 45(8):1551-7. PubMed ID: 15370206
[TBL] [Abstract][Full Text] [Related]
37. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.
Farrell K; McKay P; Leach M
Leuk Lymphoma; 2011 Oct; 52(10):1920-8. PubMed ID: 21663507
[TBL] [Abstract][Full Text] [Related]
38. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group.
Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO;
Leuk Lymphoma; 2003 Nov; 44(11):1903-10. PubMed ID: 14738141
[TBL] [Abstract][Full Text] [Related]
39. Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups.
Shankar AG; Roques G; Kirkwood AA; Lambilliotte A; Freund K; Leblanc T; Hayward J; Abbou S; Ramsay AD; Schmitt C; Gorde-Grosjean S; Pacquement H; Haouy S; Boudjemaa S; Aladjidi N; Hall GW; Landman-Parker J
Br J Haematol; 2017 Apr; 177(1):106-115. PubMed ID: 28220934
[TBL] [Abstract][Full Text] [Related]
40. [Nodular lymphocyte-predominant Hodgkin's lymphoma: Principles of diagnosis and treatment].
Moiseeva TN; Al-Radi LS; Kovrigina AM; Goryacheva SR; Julakyan UL; Margolin OV; Skidan NI; Tseytlina MA; Kravchenko SK
Ter Arkh; 2015; 87(11):78-83. PubMed ID: 26821421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]